Navigation Links
Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
Date:9/3/2008

MADISON, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced the appointment of Daniel J. McIntyre, 54, to Vice President, Corporate Communications. Reporting to Timothy P. Cost, Senior Vice President, Corporate Affairs, Mr. McIntyre will be responsible for all internal and external communications for the corporation and its three major divisions -- pharmaceuticals, consumer health care and animal health -- around the world.

Prior to joining Wyeth, Mr. McIntyre held a series of senior executive positions in communications and health care. Most recently, he was Managing Director of the healthcare practice of Fleishman-Hillard International Communications. He previously served in senior level Communications and Public Policy positions for Pharmacia Corporation, Bayer Corporation's Pharmaceutical Division, the Bristol-Myers Squibb Company, and Hoffmann-La Roche Inc.

"Wyeth is in one of the most important periods in its history," says Mr. Cost. "We are building momentum toward developing new therapies for patients even as we transform our organization for the future. Having Dan now leading our communications team is an important part of our plan to meet new and evolving challenges."

An honors graduate of Seton Hall University, McIntyre holds an MPA from Rutgers University. He is a member of the executive committee of the Rutgers University Foundation, and has served on the boards of trustees of Caldwell College, the American Association for World Health, the New England Healthcare Institute (NEHI) and Connecticut United for Research Excellence (CURE). He is also a member of the Public Relations Society of America (PRSA).

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
2. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
3. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
4. Wyeth Declares Common and Preferred Stock Dividends
5. Wyeth Pharmaceuticals Announces Organizational Change
6. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
7. Wyeth to Present at the 2008 Citi Investment Research Global Healthcare Conference
8. Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement
9. Wyeth Chairman Robert Essner Announces June 27 Retirement
10. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
11. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
Breaking Biology Technology:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a medical ... (IV) therapy, today announced receipt of its ISO 13485 Certification, the ... the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection ... "This is an important ...
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
Breaking Biology News(10 mins):